OWCP (OWC Pharmaceutical Research) LT-Debt-to-Total-Asset: 0.01 (As of Sep. 2019)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is OWC Pharmaceutical Research LT-Debt-to-Total-Asset?

OWC Pharmaceutical Research OWCP LT-Debt-to-Total-Asset is 0.01 as of Sep. 2019.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. OWC Pharmaceutical Research's long-term debt to total assests ratio for the quarter that ended in Sep. 2019 was 0.01.

OWC Pharmaceutical Research's long-term debt to total assets ratio increased from Sep. 2018 (0.00) to Sep. 2019 (0.01). It may suggest that OWC Pharmaceutical Research is progressively becoming more dependent on debt to grow their business.

OWC Pharmaceutical Research  (OTCPK:OWCP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

OWC Pharmaceutical Research LT-Debt-to-Total-Asset Related Terms

OWC Pharmaceutical Research LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for OWC Pharmaceutical Research's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OWC Pharmaceutical Research LT-Debt-to-Total-Asset Chart

OWC Pharmaceutical Research Annual Data
Trend Dec08 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.50 0.00 0.00

OWC Pharmaceutical Research Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.01 0.01 0.01

OWC Pharmaceutical Research LT-Debt-to-Total-Asset Calculation

OWC Pharmaceutical Research's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2018 is calculated as

LT Debt to Total Assets (A: Dec. 2018 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2018 )/Total Assets (A: Dec. 2018 )
=0/3.553
=

OWC Pharmaceutical Research's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2019 is calculated as

LT Debt to Total Assets (Q: Sep. 2019 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2019 )/Total Assets (Q: Sep. 2019 )
=0.021/1.773
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.01 mean?
OWC Pharmaceutical Research (OWCP) has a LT-Debt-to-Total-Asset of 0.01 as of Sep. 2019. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on OWC Pharmaceutical Research and its competitors.
Is OWC Pharmaceutical Research's LT-Debt-to-Total-Asset too high?
OWC Pharmaceutical Research's current LT-Debt-to-Total-Asset is 0.01.
How does OWC Pharmaceutical Research's LT-Debt-to-Total-Asset compare to PARNF and CANB?
OWC Pharmaceutical Research's LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on OWC Pharmaceutical Research and its competitors. OWC Pharmaceutical Research's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OWC Pharmaceutical Research stock overvalued right now?
OWC Pharmaceutical Research (OWCP) has a current LT-Debt-to-Total-Asset of 0.01. The current LT-Debt-to-Total-Asset is 0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For OWC Pharmaceutical Research (OWCP), the current LT-Debt-to-Total-Asset is 0.01 as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OWC Pharmaceutical Research Business Description

Address 2 Ben Gurion Street, Ramat Gan, ISR, 4514760
OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.